Thanks, Pete. I'll provide a brief overview, and of course, welcome all of you to review our filings in greater detail for reach out team with questions you may have. During the quarter ended June 30, 2022, we reported consolidated revenue of $18.1 million, a net loss of $4.8 million and adjusted EBITDA of $2.7 million. For the same period last year, we reported consolidated revenue of $16.3 million, a net loss from continuing operations of $1.1 million and adjusted EBITDA of $3.5 million. For fiscal 2022, we generated $68.0 million of revenue, a net loss of $15.0 million and adjusted EBITDA of $9.3 million on a consolidated basis. That compared to revenue of $60.9 million, a net loss of $8.5 million and adjusted EBITDA of $8.6 million for fiscal 2021. Great Elm reports the results of each of our two operating segments including Investment Management and Durable Medical Equipment as well as unallocated general corporate activity. We'll begin the review with Investment Management. For the fiscal fourth quarter, Investment Management reported total revenue of $1.5 million compared to $0.9 million during the same period in the prior year. For fiscal 2022, our Investment Management business generated $4.5 million in revenue compared to $3.2 million in the prior fiscal year. The increase primarily reflected higher assets under management at GECC related to market recoveries and the successful completion of rights offerings, as well as incremental management fees earned from Monomoy REIT, which was acquired in May 2022. As a reminder, Investment Management earns an asset management fee equal to 1% of the REIT's NAV, in addition to property management fees equivalent to 4% of gross rents collected. For the quarter, Investment Management reported a net loss of $1.8 million in comparison to net income of $1.3 million in the prior period. Notably, non-operating activity related to our investment in Monomoy REIT, including dividend income and unrealized gains and losses are now presented as investment management activity given our recent acquisition of the management agreement, whereas previously, they are presented within general corporate. We believe this presentation provides a better view into the performance of the segment. For the year, Investment Management recognized a net loss of $8.6 million as compared to net income of $2.7 million in fiscal 2021. The variance primarily related to non-operating net realized and unrealized losses on the Company's managed investments, primarily GECC, of $7.8 million during the year ended June 30, 2022, as compared to net gains of $0.7 million during the year ended June 30, 2021. Adjusted EBITDA was negative $72,000 in fiscal 2022 fourth quarter compared to a positive $95,000 during the same period in the prior year. For fiscal 2022, adjusted EBITDA was negative $0.4 million as compared to positive $0.4 million in fiscal 2021, as higher payroll costs and consulting fees related to the Monomoy REIT's acquisition and other investments to fuel investment management growth outpaced the increase in revenue. Next, turning to Durable Medical Equipment. For the fiscal fourth quarter, DME generated $16.5 million in revenue compared to $15.4 million for the same period last year, primarily reflecting more efficient intake and collections processes driving lower revenue reserve rates. For the year ended June 30, 2022, DME revenues were up 10.1% to $63.5 million compared to $57.7 million in the prior fiscal year. The increase in total revenue was due primarily to these operating efficiencies as well as contributions from the acquisitions of AMPM in March 2021 and MedOne in August 2021. Looking ahead, we expect global supply chain issues, which restrict our ability to procure certain respiratory equipment to persist in the near term. But we continue to work with key suppliers and explore alternative sourcing to minimize the impact to our business. Great Elm's DME operations reported a net loss of $0.2 million in comparison to net income of $5.9 million in the prior year period. Despite the 7.6% quarter-over-quarter increase in revenue, the decline in net income mostly reflected recurring valuation adjustments of an embedded derivative on an intercompany instrument, which are eliminated in consolidation and added back for EBITDA purposes as well as higher interest expense. DME reported a net loss of $3.8 million for the year ended June 30, 2022, compared to a net loss of $2.5 million in the prior year. The decrease in net income comes despite improvements in operating income at DME, which increased from $2.6 million to $4.3 million in the current year. This improvement is noteworthy given that the prior year period included $4.6 million in CARES Act stimulus, whereas only $2.3 million of CARES Act stimulus was recognized in the current year. The improvements in operating income, however, were offset by non-operating activity, primarily intercompany charges related to DME's preferred stock that is issued to a consolidated subsidiary. Such impacts, including mark-to-market adjustments on the embedded derivative and losses on voluntary redemptions, are eliminated in consolidation with offsetting impacts in general corporate. Adjusted EBITDA was $3.6 million for the fiscal fourth quarter compared to $4.3 million in the prior year period. The prior period included a $2.3 million benefit related to employee retention payroll tax credits claimed under the CARES Act, whereas no benefit was recorded during the quarter ended June 30, 2022. Excluding such benefits in the prior year period, segment profitability significantly improved versus the prior year quarter. For fiscal 2022, adjusted EBITDA was $13.8 million compared to $12.4 million in fiscal 2021, with the increase primarily driven by more favorable revenue and gross margins, partially offset by higher employee-related costs associated with acquired AMPM and MedOne employees. The prior year results included $4.6 million in CARES Act stimulus, whereas the current fiscal year includes $2.3 million, which further serves to highlight the operating improvements in the DME segment. Moving on to our General Corporate segment. For the fiscal fourth quarter, Great Elm's General Corporate segment recorded $230,000 in revenue compared to $280,000 during the same period in the prior year. For the year ended June 30, 2022, the General Corporate segment recognized $0.9 million in revenue compared to $0.6 million in the prior year. Revenue increased as a result of increased management fees earned from our management agreement with Forest, which was executed in December 2020. Such revenues are eliminated in consolidation. For the fiscal fourth quarter 2022, General Corporate reported a net loss of $2.8 million compared to a net loss of $8.3 million in the prior year quarter. The quarter-over-quarter variance was mostly a function of more favorable income tax and non-operating trends in the current quarter. For the year, the General Corporate segment recorded a net loss of $2.6 million in fiscal 2022 versus a net loss of $8.8 million in fiscal 2021. Activity impacting this comparison included higher interest income, intercompany benefits related to investments in DME preferred stock, as well as dividends and gains on our passive investment in Monomoy REIT prior to the acquisition of the investment management agreement in May 2022. In addition, fiscal 2022 incurred a tax provision of $21,000 as compared to $1.8 million of tax expense in the prior fiscal year. General Corporate adjusted EBITDA for the current quarter was negative $0.8 million compared to negative $0.9 million in the prior year period. For fiscal 2022, General Corporate adjusted EBITDA was negative $4.1 million compared to negative $4.2 million in fiscal 2021. Finally, in terms of our balance sheet, we ended the year with a healthy liquidity position of $23.6 million in cash exclusive of liquid investments. As Pete alluded to earlier, during the quarter, we issued $27 million in aggregate principal amount of 7.25% notes due 2027 with the proceeds earmarked for strategic growth investments into Monomoy REIT as part of the transaction, and other opportunistic investments to further build and diversify the investment management business. In May, we also issued $6.3 million promissory note as part of a non-cash upfront consideration for the acquisition of Monomoy REIT. The 6.5% note is due in 2023 and is payable with either cash, GECC shares owned by GEG or newly issued GEG shares subject to shareholder approval. This concludes my financial review of the quarter. And with that, we'll turn the call over to the operator to open for questions.